(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Unsold Rams May Be Less expensive Than You Suspect - 2Corcept Therapeutics shares surge as lead drug gets FDA nod for ovarian cancer
- 3Getting Your Youngsters' Future: Grasping Legacy Regulations
- 4Navy-Marine Corps Relief Society provides emergency grants to families displaced by Iran war
- 5Bolsonaro discharged from hospital and placed under house arrest
- Cyprus urges hotels to open up, pours funding into tourism
- Mississippi Insight for Jan. 11, 2026
- Step by step instructions to Contrast Lab Jewels and Regular Ones
- Argentina joins NASA’s moon return with microsatellite testing GPS beyond Earth
- Spots To Go Birdwatching All over the Planet
- Giant ‘toothed’ birds flew over Antarctica 40 million to 50 million years ago
- The EU Is Considering Lifting Tariffs on Chinese Electric Vehicles
- Nikki Glaser has been testing out Golden Globes jokes. There's one nobody wants to hear
- Congo declares its latest Ebola outbreak over, after 43 deaths
